No paper directly addresses synthetic data as a PHI-avoiding substrate for pre-data-lock analysis code development. The literature recognizes simulation for trial prep, synthetic data validity, and pipeline validation — but no one has connected these into a "workflow utility" paradigm distinct from clinical mimicry.
Taekman + Dadiz/Guillet (2024–2026) on simulation for trial preparation — operational focus, not data-centric.
TrialSynth, GAN tutorials, validation studies — mature but optimized for clinical realism, not workflow utility.
DosiTest, Petalcorin — validate workflows with simulated data, but target analytic outputs not code development.
Synthetic data that exercises analysis code paths without PHI exposure: a novel concept with structural fidelity as its core insight.
Key insight: JCTS editors are actively receptive to pre-trial methodology papers. But all three focus on operational simulation — not data-centric pipeline preparation.
VAE + Hawkes Processes. State-of-the-art fidelity for time-sequence clinical trial data. arXiv.
Validates synthetic data as statistical proxy for real trial data. BMJ Open. 94 citations.
GAN tutorial for synthetic clinical prediction data. JCTS.
Longitudinal synthetic data for breast cancer translational research. JCO CCI.
The misalignment: Every paper evaluates synthetic data by clinical realism. None asks: what if fidelity to real patients isn't the goal?
But: DosiTest evaluates existing workflows for uncertainty, and Petalcorin targets exploratory analytics. Neither addresses pre-data-lock code development.
| Clinical Mimicry | Workflow Utility |
|---|---|
| Goal: synthetic ≈ real patients | Goal: synthetic exercises analysis code |
| Requires distributional fidelity | Requires structural fidelity only |
| High generation complexity | Lower bar — simpler methods viable |
| Evaluated by statistical similarity | Evaluated by pipeline readiness |
Structural fidelity: matching variable names, data types, visit structures, missingness patterns, and analysis metadata. Enough to write and validate all analysis code before data lock — without touching PHI.
Strategic fit: This paper would extend the existing JCTS conversation from operational simulation into the synthetic data domain — a natural and novel bridge.
Retrieve full JCTS papers — PMC full texts of Taekman, Guillet/Dadiz, and Dadiz et al. to verify the data-centric angle isn't already addressed.
Trace citation graphs — Forward/backward citations on Taekman (2026) and DosiTest (2022).
Draft the novelty claim — Articulate "workflow utility" vs. "clinical mimicry" with structural fidelity as the core concept.
Confirm JCTS timeline — Special issue submission deadline and requirements.
Expand gray literature — CTSA proceedings, AMIA abstracts, clinical informatics conferences.
Tier guide: Tier 1 = Primary institutional source (peer-reviewed journal or official publication) · Tier 2 = Preprint or non-peer-reviewed source — verify independently
Generated May 22, 2026 · DeepSeek V4 Pro · research-rapid v1.0 · Gambit / brief-to-slides v2.0